Skip to main content
SpringerLink
Log in

Molecular Genetics and the Treatment of Addiction

  • Chapter
  • First Online:
Addiction Medicine

  • 5168 Accesses

Abstract

Substance use disorders represent complex phenotypes that result from the intricate interplay of genetic variation, neurobiological mechanisms, and psychosocial and environmental variables. To date, one of the least studied factors has been genetic variation. This chapter provides a critical review of the expanding literature on molecular genetics applied to the treatment of addiction. We begin with a brief overview of concepts in psychiatric genetics, followed by an extended review and discussion of pharmacogenetics and pharmacogenomics applied to addiction medicine. Next, we discuss practical and ethical issues in the translation of pharmacogenetics science into clinical practice. Lastly, we outline future directions for the field. Although personalized medicine is still largely incipient in the field of addiction, it holds considerable potential to improve the clinical care of individuals suffering from addictive disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Aitchison KJ, Jordan BD, Sharma T (2000) The relevance of ethnic influences on pharmacogenetics to the treatment of psychosis. Drug Metabol Drug Interact 16(1):15–38

    Article  PubMed  CAS  Google Scholar 

  2. Alexanderson B (1973) Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics: a study in twins. Eur J Clin Pharmacol. 6(1):44–53

    Article  PubMed  CAS  Google Scholar 

  3. Anton RF, Oroszi G, O’Malley S et al (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) study. Arch Gen Psychiatry 65(2):135–144

    Article  PubMed  CAS  Google Scholar 

  4. Arias AJ, Armeli S, Gelernter J et al (2008) Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res. 32(7):1159–1166

    Article  PubMed  CAS  Google Scholar 

  5. Bauer LO, Covault J, Harel O et al (2007) Variation in GABRA2 predicts drinking behavior in project MATCH subjects. Alcohol Clin Exp Res 31(11):1780–1787

    Article  PubMed  CAS  Google Scholar 

  6. Berrettini WH, Lerman CE (2005) Pharmacotherapy and pharmacogenetics of nicotine dependence. Am J Psychiatry 162(8):1441–1451

    Article  PubMed  Google Scholar 

  7. Bierut LJ, Dinwiddie SH, Begleiter H et al (1998) Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: a report from the collaborative study on the genetics of alcoholism. Arch Gen Psychiatry 55(11):982–988

    Article  PubMed  CAS  Google Scholar 

  8. Bond C, LaForge KS, Tian M et al (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95(16):9608–9613

    Article  PubMed  CAS  Google Scholar 

  9. Boomsma DI, Willemsen G, Sullivan PF et al (2008) Genome-wide association of major depression: description of samples for the GAIN major depressive disorder study: NTR and NESDA biobank projects. Eur J Hum Genet 16(3):335–342

    Article  PubMed  CAS  Google Scholar 

  10. Cohen BM, Ennulat DJ, Centorrino F et al (1999) Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology (Berl) 141(1):6–10

    Article  CAS  Google Scholar 

  11. Craddock N, O’Donovan MC, Owen MJ (2008) Genome-wide association studies in psychiatry: lessons from early studies of non-psychiatric and psychiatric phenotypes. Mol Psychiatry 13(7):649–653

    Article  PubMed  CAS  Google Scholar 

  12. Dole VP, Nyswander ME (1966) Rehabilitation of heroin addicts after blockade with methadone. NY State J Med 66(15):2011–2017

    CAS  Google Scholar 

  13. Ducci F, Goldman D (2008) Genetic approaches to addiction: genes and alcohol. Addiction 103(9):1414–1428

    Google Scholar 

  14. Edenberg HJ, Dick DM, Xuei X et al (2004) Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am J Hum Genet 74(4):705–714

    Article  PubMed  CAS  Google Scholar 

  15. Eisenberg DT, Mackillop J, Modi M et al (2007) Examining impulsivity as an endophenotype using a behavioral approach: a DRD2 TaqI A and DRD4 48-bp VNTR association study. Behav Brain Funct 3:2

    Article  PubMed  Google Scholar 

  16. Evans WE, Johnson JA (2001) Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2:9–39

    Article  PubMed  CAS  Google Scholar 

  17. Feldstein Ewing SW, LaChance HA, Bryan A, Hutchison KE (2009) Do genetic and individual risk factors moderate the efficacy of motivational enhancement therapy? Drinking outcomes with an emerging adult sample. Addict Biol 14(3):356–365

    Google Scholar 

  18. Feng Y, Niu T, Xing H et al (2004) A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. Am J Hum Genet 75(1):112–121

    Article  PubMed  CAS  Google Scholar 

  19. Ferreira MA, O’Donovan MC, Meng YA et al (2008) Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 14(3):356–365

    Google Scholar 

  20. Filbey FM, Ray L, Smolen A, Claus ED, Audette A, Hutchison KE (2008) Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. Alcohol Clin Exp Res 32(7):1113–1123

    Article  PubMed  Google Scholar 

  21. Frackiewicz EJ, Sramek JJ, Herrera JM, Kurtz NM, Cutler NR (1997) Ethnicity and antipsychotic response. Ann Pharmacother 31(11):1360–1369

    PubMed  CAS  Google Scholar 

  22. Frazer KA, Ballinger DG, Cox DR et al (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164):851–861

    Article  PubMed  CAS  Google Scholar 

  23. Goldstein DB, Tate SK, Sisodiya SM (2003) Pharmacogenetics goes genomic. Nat Rev Genet 4(12):937–947

    Article  PubMed  CAS  Google Scholar 

  24. Gordis E (2000) Contributions of behavioral science to alcohol research: understanding who is at risk and why. Exp Clin Psychopharmacol 8(3):264–270

    Article  PubMed  CAS  Google Scholar 

  25. Gottesman II, Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160(4):636–645

    Article  PubMed  Google Scholar 

  26. Gould TD, Gottesman II (2006) Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav 5(2):113–119

    Article  PubMed  CAS  Google Scholar 

  27. Grove WM, Eckert ED, Heston L, Bouchard TJ Jr, Segal N, Lykken DT (1990) Heritability of substance abuse and antisocial behavior: a study of monozygotic twins reared apart. Biol Psychiatry 27(12):1293–1304

    Article  PubMed  CAS  Google Scholar 

  28. Gynther LM, Carey G, Gottesman II, Vogler GP (1995) A twin study of non-alcohol substance abuse. Psychiatry Res 56(3):213–220

    Article  PubMed  CAS  Google Scholar 

  29. Haile CN, Kosten TA, Kosten TR (2008) Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 34(4):355–381

    Article  PubMed  Google Scholar 

  30. Hammer W, Sjoqvist F (1967) Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci 6(17):1895–1903

    Article  PubMed  CAS  Google Scholar 

  31. Haughey HM, Ray LA, Finan P, Villanueva R, Niculescu M, Hutchison KE (2008) Human gamma-aminobutyric acid A receptor alpha2 gene moderates the acute effects of alcohol and brain mRNA expression. Genes Brain Behav 7(4):447–454

    Article  PubMed  CAS  Google Scholar 

  32. Heils A, Teufel A, Petri S et al (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66(6):2621–2624

    Article  PubMed  CAS  Google Scholar 

  33. Hernandez-Avila CA, Covault J, Wand G, Zhang H, Gelernter J, Kranzler HR (2007) Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenet Genomics 17(12):1031–1038

    Article  PubMed  CAS  Google Scholar 

  34. Hines LM, Ray L, Hutchison K, Tabakoff B (2005) Alcoholism: the dissection for endophenotypes. Dialogues Clin Neurosci 7(2):153–163

    PubMed  Google Scholar 

  35. Hutchison KE, Allen DL, Filbey FM et al (2007) CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry 64(9):1078–1086

    Article  PubMed  CAS  Google Scholar 

  36. Hutchison KE, McGeary J, Smolen A, Bryan A, Swift RM (2002) The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychol 21(2):139–146

    Article  PubMed  Google Scholar 

  37. Hutchison KE, Ray L, Sandman E et al (2006) The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 31(6):1310–1317

    PubMed  CAS  Google Scholar 

  38. Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida A (2001) Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (Berl) 155(1):27–34

    Article  CAS  Google Scholar 

  39. Hutchison KE, Wooden A, Swift RM et al (2003) Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 28(10):1882–1888

    Article  PubMed  CAS  Google Scholar 

  40. Hutchison KE (2008) Alcohol dependence: neuroimaging and the development of translational phenotypes. Alcohol Clin Exp Res 32(7):1111–1112

    Article  PubMed  Google Scholar 

  41. International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437(7063):1299–1320

    Article  Google Scholar 

  42. Johnstone EC, Yudkin PL, Hey K et al (2004) Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14(2):83–90

    Article  PubMed  CAS  Google Scholar 

  43. Karila L, Gorelick D, Weinstein A et al (2008) New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 11(3):425–438

    Article  PubMed  CAS  Google Scholar 

  44. Kendler KS, Neale MC, Heath AC, Kessler RC, Eaves LJ (1994) A twin-family study of alcoholism in women. Am J Psychiatry 151(5):707–715

    PubMed  CAS  Google Scholar 

  45. Kendler KS, Prescott CA, Myers J, Neale MC (2003) The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry 60(9):929–937

    Article  PubMed  Google Scholar 

  46. Kendler KS, Prescott CA (1998) Cannabis use, abuse, and dependence in a population-based sample of female twins. Am J Psychiatry 155(8):1016–1022

    PubMed  CAS  Google Scholar 

  47. Kendler KS, Prescott CA (1998) Cocaine use, abuse and dependence in a population-based sample of female twins. Br J Psychiatry 173:345–350

    Article  PubMed  CAS  Google Scholar 

  48. Kendler KS, Thornton LM, Pedersen NL (2000) Tobacco consumption in Swedish twins reared apart and reared together. Arch Gen Psychiatry 57(9):886–892

    Article  PubMed  CAS  Google Scholar 

  49. Kirchheiner J, Nickchen K, Bauer M et al (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9(5):442–473

    Article  PubMed  CAS  Google Scholar 

  50. Kranzler HR, Covault J, Pierucci-Lagha A et al (2008) Effects of aripiprazole on subjective and physiological responses to alcohol. Alcohol Clin Exp Res 32(4):573–579

    Article  PubMed  CAS  Google Scholar 

  51. Kreek MJ, Vocci FJ (2002) History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 23(2):93–105

    Article  PubMed  Google Scholar 

  52. Lerman C, Jepson C, Wileyto EP et al (2006) Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31(1):231–242

    PubMed  CAS  Google Scholar 

  53. Lerman C, Kaufmann V, Rukstalis M et al (2004) Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med 140(6):426–433

    PubMed  CAS  Google Scholar 

  54. Lerman C, Tyndale R, Patterson F et al (2006) Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 79(6):600–608

    Article  PubMed  CAS  Google Scholar 

  55. Lerman C, Wileyto EP, Patterson F et al (2004) The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 4(3):184–192

    Article  PubMed  CAS  Google Scholar 

  56. Li MD, Beuten J, Ma JZ et al (2005) Ethnic- and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence. Hum Mol Genet 14(9):1211–1219

    Article  PubMed  CAS  Google Scholar 

  57. Lin E, Hwang Y, Liang KH, Chen EY (2007) Pattern-recognition techniques with haplotype analysis in pharmacogenomics. Pharmacogenomics 8(1):75–83

    Article  PubMed  CAS  Google Scholar 

  58. Mackillop J, Menges DP, McGeary JE, Lisman SA (2007) Effects of craving and DRD4 VNTR genotype on the relative value of alcohol: an initial human laboratory study. Behav Brain Funct 3:11

    Article  PubMed  Google Scholar 

  59. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF (2006) Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 11(4):400–409

    Article  PubMed  CAS  Google Scholar 

  60. Mattick RP, Kimber J, Breen C, Davoli M (2004) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev CD002207

    Google Scholar 

  61. McLeod HL, Evans WE (2001) Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 41:101–121

    Article  PubMed  CAS  Google Scholar 

  62. Monti PM, Rohsenow DJ, Swift RM et al (2001) Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 25(11):1634–1647

    Article  PubMed  CAS  Google Scholar 

  63. Munafo MR, Johnstone EC, Wileyto EP, Shields PG, Elliot KM, Lerman C (2006) Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 15(2):398–400

    Article  PubMed  CAS  Google Scholar 

  64. Munafo MR, Shields AE, Berrettini WH, Patterson F, Lerman C (2005) Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics 6(3):211–223

    Article  PubMed  CAS  Google Scholar 

  65. O’Donovan MC, Craddock N, Norton N et al (2008) Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet

    Google Scholar 

  66. Oslin DW, Berrettini W, Kranzler HR et al (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28(8):1546–1552

    Article  PubMed  CAS  Google Scholar 

  67. Ozaki S, Oyama T, Isse T et al (2006) Smoking cessation program and CYP2A6 polymorphism. Front Biosci 11:2590–2597

    Article  PubMed  CAS  Google Scholar 

  68. Pearson TA, Manolio TA (2008) How to interpret a genome-wide association study. JAMA 299(11):1335–1344

    Article  PubMed  CAS  Google Scholar 

  69. Perez de los Cobos J, Sinol N, Trujols J et al (2007) Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 89(2–3):190–194

    Article  Google Scholar 

  70. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH (1996) Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 51(3–4):289–295

    Article  PubMed  CAS  Google Scholar 

  71. Rausch JL, Johnson ME, Fei YJ et al (2002) Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 51(9):723–732

    Article  PubMed  CAS  Google Scholar 

  72. Ray LA, Bryan A, Mackillop J, McGeary J, Hesterberg K, Hutchison KE (2009) The dopamine D Receptor (DRD4) gene exon III polymorphism, problematic alcohol use and novelty seeking: direct and mediated genetic effects. Addict Biol 14(2):238–244

    Google Scholar 

  73. Ray LA, Hutchison KE, Bryan A (2006) Psychosocial predictors of treatment outcome, dropout, and change processes in a pharmacological clinical trial for alcohol dependence. Addict Disorders Treat 5(4):179–190

    Article  Google Scholar 

  74. Ray LA, Hutchison KE (2004) A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28(12):1789–1795

    Article  PubMed  CAS  Google Scholar 

  75. Ray LA, Hutchison KE (2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 64(9):1069–1077

    Article  PubMed  CAS  Google Scholar 

  76. Ray LA, MacKillop J, Leggio L, Morgan M, Hutchison KE (2009) Effects of naltrexone on cortisol levels in heavy drinkers. Pharmacol Biochem Behav 91(4):489–494

    Google Scholar 

  77. Ray LA, MacKillop J, Monti PM Subjective responses to alcohol as endophenotypes: advancing genetics into etiological and treatment models of alcoholism. Subst Use Misuse

    Google Scholar 

  78. Ray LA, Meskew-Stacer S, Hutchison KE (2007) The relationship between prospective self-rating of alcohol sensitivity and craving and experimental results from two alcohol challenge studies. J Stud Alcohol Drugs 68(3):379–384

    PubMed  Google Scholar 

  79. Ray R, Jepson C, Patterson F et al (2006) Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl) 188(3):355–363

    Article  CAS  Google Scholar 

  80. Ray R, Schnoll RA, Lerman C (2007) Pharmacogenetics and smoking cessation with nicotine replacement therapy. CNS Drugs 21(7):525–533

    Article  PubMed  CAS  Google Scholar 

  81. Rioux PP (2000) Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am J Health Syst Pharm 57(9):887–898; quiz 899–901

    PubMed  CAS  Google Scholar 

  82. Schuckit MA, Smith TL, Kalmijn J (2004) The search for genes contributing to the low level of response to alcohol: patterns of findings across studies. Alcohol Clin Exp Res 28(10):1449–1458

    Article  PubMed  CAS  Google Scholar 

  83. Schuckit MA, Smith TL (1996) An 8-year follow-up of 450 sons of alcoholic and control subjects. Arch Gen Psychiatry 53(3):202–210

    Article  PubMed  CAS  Google Scholar 

  84. Shields AE, Blumenthal D, Weiss KB, Comstock CB, Currivan D, Lerman C (2005) Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians. J Gen Intern Med 20(2):131–138

    Article  PubMed  Google Scholar 

  85. Shields AE, Burke W, Levy DE (2008) Differential use of available genetic tests among primary care physicians in the United States: results of a national survey. Genet Med 10(6):404–414

    Article  PubMed  Google Scholar 

  86. Shields AE, Lerman C (2008) Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready? Clin Pharmacol Ther 83(4):635–639

    Article  PubMed  CAS  Google Scholar 

  87. Shields AE, Levy DE, Blumenthal D et al (2008) Primary care physicians’ willingness to offer a new genetic test to tailor smoking treatment, according to test characteristics. Nicotine Tob Res 10(6):1037–1045

    Article  PubMed  Google Scholar 

  88. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M (1998) Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3(6):508–511

    Article  PubMed  CAS  Google Scholar 

  89. Teo YY (2008) Common statistical issues in genome-wide association studies: a review on power, data quality control, genotype calling and population structure. Curr Opin Lipidol 19(2):133–143

    Article  PubMed  CAS  Google Scholar 

  90. The International HapMap Project (2003) Nature 426(6968):789–796

    Article  Google Scholar 

  91. Tidey JW, Monti PM, Rohsenow DJ et al (2008) Moderators of naltrexone’s effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 32(1):58–66

    Article  PubMed  CAS  Google Scholar 

  92. Tsuang MT, Lyons MJ, Eisen SA et al (1996) Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am J Med Genet 67(5):473–477

    Article  PubMed  CAS  Google Scholar 

  93. Tsuang MT, Lyons MJ, Meyer JM et al (1998) Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 55(11):967–972

    Article  PubMed  CAS  Google Scholar 

  94. Tyndale RF, Droll KP, Sellers EM (1997) Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 7(5):375–379

    Article  PubMed  CAS  Google Scholar 

  95. Uhl GR, Liu QR, Drgon T et al (2008) Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 65(6):683–693

    Article  PubMed  CAS  Google Scholar 

  96. van den Wildenberg E, Wiers RW, Dessers J et al (2007) A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res 31(1):1–10

    Article  PubMed  Google Scholar 

  97. Vogel F (1959) Moderne probleme der humangenetik. Ergeb Inn Med U Kinderheilkd 12:52–125

    Article  Google Scholar 

  98. Vojvoda D, Grimmell K, Sernyak M, Mazure CM (1996) Monozygotic twins concordant for response to clozapine. Lancet 347(8993):61

    Article  PubMed  CAS  Google Scholar 

  99. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E (2000) Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 20(1):105–107

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychology, University of California, Los Angeles, CA, USA

    Lara A. Ray

  2. Department of Psychology, University of New Mexico, Albuquerque, NM, USA

    Kent E. Hutchison

Authors
  1. Lara A. Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kent E. Hutchison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lara A. Ray .

Editor information

Editors and Affiliations

  1. , Depts Psychiat & Neurobehav Sciences, Me, University of Virginia, Charlottesville, 22908, Virginia, USA

    Bankole A. Johnson

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ray, L.A., Hutchison, K.E. (2010). Molecular Genetics and the Treatment of Addiction. In: Johnson, B. (eds) Addiction Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0338-9_55

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-0338-9_55

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-0337-2

  • Online ISBN: 978-1-4419-0338-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation